He became interested in biomedical research right from childhood and started writing articles in high school. He graduated in medicine and began practicing internal medicine. However, he was more interested in medical research. He joined the Department of Pharmacology at King George's Medical University, Lucknow, India, and then got an appointment at the Central Drug Research Institute, Lucknow, India. His interest in medical research continued, and he received an offer from the University of Illinois at Chicago, Chicago, Illinois, USA. He accepted the offer and worked for about 20 years at the University of Illinois at Chicago. He was offered a Professorship and Associate Dean position at the Midwestern University, Illinois, USA. He worked at Midwestern University for about 15 years. His research became meaningful, with results that could significantly impact patients with unmet medical needs. He founded Pharmazz, Inc. in 2010, intending to translate his laboratory findings to develop novel drug products that could ultimately treat patients. In 2019, he became full-time Chairman and CEO of Pharmazz, Inc. because the Company he founded needed a lot more of his time to grow and move to the next step of translating his research to benefit patients. His ambition of bringing novel drug products to treat patients has succeeded, resulting in Sovateltide, a drug to treat cerebral stroke, and a second product, Centhaquine, to treat hypovolemic shock. These drugs are being marketed in India to treat patients. Centhaquine and Sovateltide have approved Phase 3 Investigational New Drug (IND) applications and a Special Protocol Assessment (SPA) with the US FDA, indicating significant progress in his ambition to have a global reach and make his inventions available to patients worldwide.

Prof. (Dr.) Anil Gulati is a highly accomplished and innovative figure in biopharmaceutical. His ability to identify critical unmet medical needs, translate fundamental scientific concepts into novel therapeutic agents, and successfully navigate the complex drug development and commercialization pathways is genuinely remarkable. The success of Sovateltide and Centhaquine in India and their progression through late-stage US clinical trials underscore the potential for Dr. Gulati's inventions to impact global healthcare significantly. His dedication to scientific advancement and mentorship further solidifies his position as a prominent leader in medical innovation.